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Background and aim: Safe and effective treatments are required for patients with 
ulcerative colitis. It was suggested that granulocytes and monocytes adsorption 
apheresis could play an important role in treatment for ulcerative colitis. Therefore, a 
meta-analysis was performed to investigate the usefulness of granulocytes and 
monocytes adsorption apheresis for ulcerative colitis. 
Methods: Medline and the Cochrane controlled-trials register were used to identify 
randomized controlled-trials comparing granulocytes and monocytes adsorption 
apheresis with corticosteroids, intensive with conventional apheresis in patients with 
ulcerative colitis. 
Results: Nine randomized-trials were eligible for inclusion criteria. According to pooled 
data, granulocytes and monocytes adsorption apheresis is effective for inducing clinical 
remission in patients with ulcerative colitis compared with corticosteroids (odds ratio, 
2.23; 95% confidence interval: 1.38-3.60). However, the efficacy of granulocytes and 
monocytes adsorption apheresis was not dependent on the number of apheresis-sessions. 
The intensive-apheresis (≥2 sessions per week) is more effective for inducing clinical 
remission than weekly-apheresis (odds ratio, 2.10; 95% confidence interval: 1.12-3.93). 
The rate of adverse events by apheresis was significantly lower than that by 




corticosteroids (odds ratio, 0.24; 95% confidence interval: 0.15-0.37). 
Conclusion: Our meta-analysis reveals that intensive granulocytes and monocytes 
adsorption apheresis is a safe and effective treatment with higher rates of clinical 
remission and response for ulcerative colitis compared with corticosteroids. 
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Ulcerative colitis (UC) is a chronic relapsing gastrointestinal disorder characterized by 
inflammation of the colonic mucosa [1]. 5-aminosalicylates (5-ASA) and 
corticosteroids are conventionally used as treatment for UC. 5-ASA, such as mesalazine, 
is used as initial induction and maintenance therapy for clinical remission in UC 
patients [2-4]. In patients with UC refractory to 5-ASA, administration of 
corticosteroids is considered the next main strategy for induction therapy [5, 6]. Recent 
evidence indicates that calcineurin inhibitors and anti-tumor necrosis factor (TNF)-α 
agents are effective treatments for patients with UC refractory to corticosteroids [7-10]. 
These immunosuppressive therapies, however, are associated with several adverse 
events, such as opportunistic infection, infusion reaction and bone marrow suppression 
[11, 12]. Moreover, resent reports suggest that the combination therapy with 
immunomodulators and anti TNF-α agents is associated with an increased risk of 
malignancy, such as malignant lymphoma [13, 14]. Therefore, less hazardous and safer 
long-term treatments are needed for maintenance of clinical remission in patients with 
UC.  
The pathophysiology of UC remains unclear. UC is associated with an increase in 
circulating leukocytes and immune complexes [15, 16]. Neutrophil granulocytes and 




monocytes/macrophages produce proinflammatory cytokines such as TNF-α and 
interferon (IFN)-γ, and these proinflammatory cytokines contribute to intestinal 
inflammation in UC [17, 18]. The level of fecal calprotectin, a member of the 
Ca
2+
-binding S100 family of proteins that is expressed in the cytoplasm of activated 
neutrophils and has proinflammatory properties, is related to the severity of UC [19], 
suggesting that removal of circulating neutrophil granulocytes is a theoretically rational 
treatment for UC. 
Granulocyte and monocyte adsorption apheresis (GMAA) using Adacolumn Ⓡ 
(JIMRO, Takasaki, Gunma, Japan) to remove activated neutrophil granulocytes is thus a 
promising therapeutic option for patients with UC [20, 21]. The column is filled with 
cellulose acetate beads (leukocyte apheresis carriers) of 2 mm in diameter that are 
bathed in sterile saline. These leukocyte apheresis carriers selectively adsorb 
granulocytes and monocytes/macrophages that bear Fcγ and complement receptors. 
Several clinical trials have reported the efficacy of GMAA for treatment of UC [22, 23]. 
Moreover, intensive apheresis with more than two sessions per week induces rapid 
clinical remission in patients with active UC compared with weekly GMAA (1 session 
per week) [24]. It remains unclear, however, whether GMAA is not inferior to 
corticosteroids for inducing the remission of UC because numerous clinical trials 




reported no significant difference between GMAA and conventional treatment with 
corticosteroids. 
The aim of the study was to investigate the usefulness of GMAA for patients with 
active UC compared with corticosteroids. Moreover, we also evaluate GMAA regimens 
that are useful for the treatment of UC as sub-analysis. 
 




Materials and Methods: 
Search Strategy: A search of the medical literature was conducted using MEDLINE,  
the Cochrane controlled trials register (up to January 2012) and the abstract books of 
recent international congress, such as Digestive Disease Week 2012, 2013, and 8
th
 
Congress of European Crohn’s and Colitis Organization, to identify comparative studies 
of GMAA in patients with UC. The search terms “apheresis” and “adsorption” were 
used in combination with “inflammatory bowel disease” and “ulcerative colitis”. All 
abstracts were retrieved from the database according to this strategy.  
Inclusion criteria: Only randomized control trials were included. The populations of 
these studies comprised patients with active UC. Studies included at least two branches: 
a conventional group treated with corticosteroids and a GMAA group. Moreover, 
studies comparing GMAA regimens were included for subanalysis; for example, more 
than 10 GMAA-sessions vs. 5 GMAA-sessions, and intensive GMAA-regimens (≥2 
sessions per week) vs. weekly GMAA-regimens (1 session per week). Papers were 
included if they provided information on at least one of the following outcome 
parameters: clinical response rate, clinical remission rate, clinical disease activity index, 
steroid-sparing effect, endoscopic findings, histological findings, number of adverse 
events, and withdrawals.  




Data extraction: Data were extracted independently by two reviewers, including author, 
year, location of trial, trial design, population of studies, number of enrolled subjects, 
variety of GMAA preparations, dose of administration, and study quality. 
Assessment of bias: Risk of bias was assessed independently by two investigators as 
described in the Cochrane handbook by recording the method used to generate the 
randomization schedule, the method used to conceal allocation, whether blinding was 
implemented, the proportion of patients that completed follow-up, whether an 
intention-to treat analysis was extractable, and whether there was evidence of selective 
reporting of outcomes. 
Statistical analysis: A meta-analysis was performed with Review Manager 5.1 
(Cochrane Collaboration, Oxford, CA). The outcome measure examined was the odds 
ratios (ORs) of the clinical remission rate or clinical response rate and the ratio of 
adverse events with GMAA vs. corticosteroids by intention-to-treat analysis. Moreover, 
the outcome measure also examined the ORs of the clinical remission rate with more 
than 10 GMAA-sessions vs. 5 sessions, and intensive GMAA vs. weekly GMAA. The 
heterogeneity of these studies was assessed using the chi-square test. Forest plots were 
created for graphic display of the results. The size of a box indicates the relative weight 
of the respective study, while the line gives the 95% confidence interval (95% CI). For 




the meta-analysis result, the diamond represents the 95% CI. 





Description of studies: The search strategy identified a total of 400 citations (Figure 1). 
383 of 400 citations were excluded (Review: 97, Case Reports: 79, Letter and Editorial: 
48, Basic Research: 53, and other medical topics: 106). Seventeen of those articles were 
retrieved and evaluated in more detail. Of 17 studies, 9 were included. The 
characteristics of these 9 studies were summarized in Table 1. Of these 9, 4 studies 
compared GMAA with corticosteroids [22, 24-26], one study was sham-controlled 
double-blinded randomized trial [27], 2 studies compared more than 10 
GMAA-sessions vs. 5 GMAA-sessions [28, 29], and the remaining 2 studies compared 
an intensive GMAA-regimen (≥2 sessions per week) vs. a weekly GMAA-regimen (1 
session per week) [30, 31]. Moreover, 4 studies compared the rate of adverse events 
between GMAA and corticosteroids [22, 24, 26, 27]. Of the 17 studies, 8 were excluded, 
because 3 made no comparison with GMAA, one paper alone compared daily GMAA 
with intensive GMAA, 2 were not randomized studies, and whether or not the same 
patients were included in other studies were unclear in the remaining 2. 
Efficacy of GMAA compared with corticosteroids on clinical remission rate in 
patients with active UC: Three studies were evaluated for the efficacy of GMAA 
compared with corticosteroids on clinical remission rate in patients with active UC [22, 




24, 26]. One study was sham-controlled double-blinded randomized trial and evaluated 
for the efficacy of GMAA compared with conventional therapy including 
corticosteroids on clinical remission rate in patients with active UC [27]. There was 
heterogeneity of study characteristics, such as characteristics of enrolled patients, 
criteria used to define clinical remission and treatment protocol. Of 4 studies, 3 were 
including patients with moderately to severely active UC [22, 24, 27]. However, the 
study of Bresci, et al. was including patients with mildly active UC [26]. The studies by 
Bresci et al. and Sands et al. were used clinical activity score and Mayo score, 
respectively [26, 27]. On the other hand, original scoring based on clinical symptoms, 
endoscopic findings and inflammatory markers was used to define clinical remission in 
the remaining two studies [22, 24]. Moreover, 2 of 4 studies compared 5 weekly 
GMAA-sessions with that of corticosteroids [22, 32]. One study compared an intensive 
GMAA-regimen (2 sessions per week) with that of corticosteroids [24] and the 
remaining one study compared 10 weekly GMAA-sessions with 10 weekly 
sham-sessions [27]. All of those studies reported that the rate of clinical remission in 
patients treated with GMAA was high compared with that in patients treated with 
corticosteroids, although the difference was not statistically significant in two of four 
studies. The pooled clinical remission rate of GMAA was 33.2% (90/271 patients), 




whereas that of corticosteroids was 25.1% (50/199 patients; Figure 2A). The OR was 
2.23 (95%CI 1.38-3.60; P<0.001). Thus, GMAA would be effective for induction of 
clinical remission in patients with active UC compared with corticosteroids. 
Efficacy of GMAA compared with corticosteroids on the clinical response rate in 
patients with active UC: Five studies were identified and evaluated for efficacy of 
GMAA on the clinical response rate compared with corticosteroids in patients with 
active UC. There was heterogeneity of study characteristics, such as characteristics of 
enrolled patients, criteria used to define clinical response and treatment protocol. Of 5 
studies, 3 studies were including patients with moderately to severely active UC [22, 24, 
27]. However, the study by Nakamura, et al. was including patients with moderately 
active UC [25], and the study by Bresci, et al. was including patients with mildly active 
UC [26]. In two of 5 studies, clinical activity index scoring was used to define clinical 
response [24, 26]. Moreover, 3 of 5 studies compared 5 weekly GMAA-sessions with 
that of corticosteroids [22, 25, 26]. One study compared an intensive GMAA-regimen 
(2 sessions per week) with that of corticosteroids [24] and the remaining one study 
compared 10 weekly GMAA-sessions with 10 weekly sham-sessions [27]. All five 
studies reported that the rate of clinical response, including clinical improvement and 
remission, in patients treated with GMAA tended to be higher than that in patients 




treated with corticosteroids, although the difference was not statistically significant, 
except for in Nakamura’s report (GMAA 80%; Control 20%; P<0.05) [25] and Bresci’s 
paper (GMAA 92.5%; Control 65%; P<0.05; Figure 2B) [26]. The pooled response rate 
was higher in the GMAA group than in the corticosteroids group (169/281 [60.1%] vs. 
102/209 [48.8%]). The OR was 1.94 (95%CI 1.32-2.85; P<0.001). These data indicated 
that GMAA was effective for inducing a clinical response in patients with active UC, 
compared with corticosteroids. 
Efficacy of GMAA compared with corticosteroids in patients with severe and 
moderate active UC: We evaluated the efficacy of GMAA in patients with severely and 
moderately active UC, respectively, because the difference of disease activity of 
enrolled patients might contribute to heterogeneity for data analysis. Shimoyama, et al. 
reported that 5 of 19 patients (26.3%) with severe UC achieved clinical remission five 
weeks after treatment with GMAA, although only one of 19 patients (5.3%) achieved it 
after treatment with corticosteroids [22]. Sands, et al. also reported that, in patients with 
severe activity UC, a significant difference of remission and response rate was observed 
between GMAA group (24% and 54%, respectively) and sham group (0% and 18%, 
respectively) (P=0.03 and 0.01 for clinical remission and clinical response, respectively) 
[27]. Therefore, meta-analysis, using Shimoyama’s trial, Hanai’s trial and Sands’ trial 




that included severe UC patients, revealed that the pooled clinical remission rate of 
GMAA was 42.0% (42 of 100 patients), whereas that of corticosteroids was 23.9% (17 
of 71 patients; Figure 3A) [22, 24, 27]. The OR was 4.64 (95%CI 1.95-11.04; P<0.001). 
Four of five trials that evaluated the effect of GMAA compared with that of 
corticosteroids included patients with moderate UC. However, in Sands’ paper, the 
number of patients with moderate UC was not mentioned [27]. Therefore, meta-analysis, 
using Shimoyama’s trial, Nakamura’s trial and Bresci’s trial that mentioned the number 
of moderately active UC-patients, revealed that the pooled clinical remission rate of 
GMAA was 51.1% (43 of 84 patients), whereas that of corticosteroids was 31.3% (26 of 
83 patients; Figure 3B) [22, 25, 26]. The OR was 2.82 (95%CI 1.39-5.73; P<0.05). 
Therefore, GMAA would not be inferior to corticosteroids for induction of clinical 
remission in UC patients with not only moderately but also severely active UC. 
The clinical remission rate in UC patients treated with 10 GMAA-sessions 
compared that with 5 GMAA-sessions: Two studies reported the efficacy of 10 
GMAA-sessions on the clinical remission rate compared with 5 GMAA-sessions in 
patients with active UC [28, 29]. However, the heterogeneity of study characteristics, 
such as characteristics of enrolled patients and treatment protocol was observed as 
follows; Ricart’s trial included patients with moderately active UC [28]. Dignass’s trial 




included patients with not only moderately but also severely active UC [29]. Ricart’s 
trial compared 10 weekly GMAA-sessions with 5 weekly GMAA-sessions, whereas 
Dignass’s trial compared intensive GMAA, such as 2 apheresis per week over 2 weeks 
followed by 6 apheresis over 6 weeks, with 5 weekly GMAA-sessions. Based on the 
pooled data, the clinical remission rate of patients treated with 10 GMAA-sessions 
tended to be higher than that of patients treated with 5 GMAA-sessions upon the 
completion of GMAA treatment (41 of 93 patients (44.1%) vs. 35 of 88 patients 
(39.8%); Figure 4A). However, the OR was 1.19 (95% CI 0.66-2.16; P=0.56), and there 
was no significant difference in the clinical remission rate between 10 GMAA-sessions 
and 5 GMAA-sessions. The efficacy of GMAA was not dependent on the number of 
GMAA-sessions. 
The clinical remission rate in UC patients treated with intensive GMAA compared 
with weekly GMAA: Three studies reported the efficacy of intensive GMAA (2 or 3 
sessions per week) on the clinical remission rate compared with weekly GMAA (1 
session per week) [29-31]. Dignass’s trial included patients with not only moderately 
but also severely active UC [29]. On the other hand, the trial by Sakuraba et al. at 2008 
was included patients with moderately active UC [30], and the other trial at 2009 was 
included those with mild to moderately active UC [31]. On the basis of taking into 




consideration of the heterogeneity of enrolled patients and protocol, thus, the pooled 
data indicated that the clinical remission rate of patients treated with intensive GMAA 
was higher than that of patients treated with weekly GMAA (100 of 170 patients 
(58.8%) vs. 83 of 171 patients (48.5%); Figure 4B). The OR was 1.57 (95% CI 
1.01-2.44; P=0.05). Therefore, these data suggested that an intensive GMAA-regimen is 
suitable for achieving clinical remission in patients with active UC. 
Adverse events: The rate of adverse events was reported in four studies [22, 24, 26, 27]. 
According to those studies, frequent adverse events in the GMAA group were headache 
and flushing. Sands’ trial reported the high rate of adverse events during treatment [27]. 
Moreover, that trial alone reported serious adverse events in which the most common 
serious adverse event was exacerbation of UC in two of apheresis-treated patients and 
four of sham-treated patients, respectively. There were no patients that discontinued the 
clinical trial due to adverse events related to GMAA. There was no evidence of 
opportunistic infection in the GMAA group. Based on the pooled data, 145 of 277 
(52.3%) patients treated with GMAA experienced an adverse event (Figure 5). On the 
other hand, 137 of 203 (67.5%) patients treated with corticosteroids experienced an 
adverse event. The OR was 0.21 (95%CI 0.13-0.35; P<0.001). Therefore, the rate of 
adverse events related to GMAA was significantly lower than that related to 










 Our meta-analysis revealed that the efficacy of GMAA is not inferior to that of 
corticosteroids in the rate of clinical remission and response of patients with active UC. 
This study also revealed that GMAA is safer for patients with active UC than 
corticosteroids.  
A number of previous studies, including randomized, non-randomized, and case 
studies, reported that the rate of clinical remission and response in refractory UC 
patients treated with GMAA was higher than that in patients treated with 
corticosteroids[23, 33]. On the other hand, Sands, et al. reported that there was no 
significant difference of remission rate between UC patients treated with GMAA and 
those with sham treatment [27]. The reason of discrepancy between the report by Sands, 
et al. and the others might be related to the characteristics of enrolled patients, such as 
their disease activity and co-medications. Particularly, the possibility that the efficacy of 
GMAA treatment depends on how severe UC-activity is must be considered, because 
the heterogeneity of UC severity might affect data analysis. Yamamoto, et al. reported 
the effect of GMAA on patients with severe UC [34]. In that study, none of the patients 
with severe UC achieved clinical remission after treatment with GMAA. Nevertheless 
the negative trial by Sands, et al. was included in this study, however, our meta-analysis 




revealed that the rate of clinical remission in UC patients treated with GMAA was 
significantly higher than that of corticosteroid. Therefore, these data indicate that 
treatment with GMAA is optimal for active UC patients. 
The GMAA regimen that would be most effective for treatment of UC has not yet been 
established, although several studies have evaluated the therapeutic effects of GMAA by 
comparing GMAA regimens [28-30]. Therefore, to determine the most useful GMAA 
regimen for UC in detail, we evaluated the effect of each GMAA regimen by 
performing a meta-analysis, comparing 10 GMAA-sessions vs. 5 GMAA-sessions, and 
intensive GMAA vs. weekly GMAA. Ricart, et al. reported that the clinical remission 
rate in UC patients treated with 10 GMAA-sessions was higher than that in patients 
treated with 5 GMAA-sessions [28], while Dignass, et al. reported that the efficacy of 5 
GMAA-sessions was not inferior to that of 10 GMAA-sessions [29]. Our meta-analysis 
revealed that there was no significant difference in the clinical remission rate between 
10 GMAA-sessions and 5 GMAA-sessions, despite the difference in the duration of 
treatment between groups. Therefore, the efficacy of GMAA was not dependent on the 
number of GMAA-sessions, although two studies showed a trend toward superiority of 
treatment with 10 GMAA-sessions.  
We compared the efficacy of intensive GMAA (≥2 sessions per week) with that of 




weekly GMAA. Sakuraba, et al. reported that intensive GMAA was significantly 
superior to weekly GMAA with regard to the clinical remission rate [30, 31]. Moreover, 
the mean time to achieve clinical remission in the intensive GMAA group was 
significantly shorter than that in the weekly GMAA group. Our meta-analysis also 
revealed that the efficacy of intensive GMAA was higher than that of weekly GMAA. 
Based on these data, intensive GMAA is suitable for the induction of clinical remission 
in patients with active UC.  
Achieving mucosal healing is currently focused on the possibility of affecting the 
long-term clinical outcome of UC, because mucosal healing is associated with reduced 
rates of hospitalization and colectomy [35]. Therefore, achieving mucosal healing is an 
important therapeutic goal for patients with inflammatory bowel disease. However, 
there were a few reports about the association between treatment with GMAA and 
mucosal healing [36, 37]. Fukuchi, et al. reported the efficacy of intensive GMAA for 
achieving mucosal healing in UC patients without concomitant corticosteroids 
compared with weekly GMAA [37]. Moreover, the cumulative non-relapse ratio of UC 
patients treated with intensive GMAA was significantly higher than that of patients 
treated with weekly GMAA. These data first demonstrated that intensive GMAA would 
be favorable to weekly GMAA for achieving mucosal healing, although further studies 




are required to determine the effect of intensive GMAA for achieving mucosal healing 
in patients with active UC.  
Approximately 10% of UC patients present with severe disease, and the remaining 
90% present with mild to moderate disease activity [38, 39]. These epidemiologic 
evaluations indicate the importance of controlling mild- to moderately-active UC by 
highly therapeutic and safe treatments. Several immunosuppressive therapies, such as 
immunomodulators and anti TNF- agents, have been used for patients with refractory 
UC [8, 9, 11]. The therapeutic strategy for refractory UC remains challenging, however, 
because the use of these immunosuppressive agents is associated with an increased risk 
of adverse events. Considering that GMAA is a natural biologic treatment for 
inflammatory bowel disease [20, 21], GMAA might be a safer alternative to 
immunosuppressive therapies. Our findings indicate that GMAA is associated with a 
low frequency of adverse events in comparison with corticosteroids. The fact that none 
of the patients in previous clinical trials discontinued GMAA treatment due to adverse 
events strongly supports the safety of GMAA [22, 24, 26, 27, 40]. In addition to fewer 
side effects of GMAA, there is one possible reason why GMAA is recommended for 
active UC patients prior to corticosteroid. In general, corticosteroid can down-regulate 
the expression of Fc and complement receptors of granulocytes and 




monocytes/macrophages with which GMAA carriers selectively bind [41]. In this regard, 
administration of corticosteroid prior to GMAA might affect the therapeutic efficacy of 
GMAA. In fact, the ratio of clinical remission and response was higher in steroid-naïve 
UC patients treated with GMAA than in steroid-refractory patients [42]. Taken together, 
we considered that treatment with GMAA plays an important role in the management of 
mildly- to moderately-active UC. 
One limitation of this study concerns the difference of disease activity of patients and 
co-treatments at enrolled, which might contribute to heterogeneity for data analysis. 
Moreover, it may be argued that the biases of performance (blinding of participants and 
personnel) and detection (blinding of outcome assessment) might be high, because most 
of all studies were open-labeled randomized studies due to the characteristic of GMAA. 
Thus, postulating heterogeneity of patient’s characteristics, our meta-analysis data might 
be deliberately interpreted. 
In conclusion, our meta-analysis reveals that GMAA is a useful and safe treatment for 
patients with active UC. Further studies are needed to determine accurately when and 
how to use GMAA as a therapeutic option for UC. 
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Table 1: Characteristics of included studies in this meta-analysis 
1
Original clinical activity score: Original scoring system composed of three factors as 
follows; abdominal symptoms (abdominal pain, bloody stool and diarrhea), endoscopic 
findings of active UC (erosions, ulcers, mucous and bloody stool and indistinct vascular 
pattern) and change of serum level of C-reactive protein. Clinical remission was defined 
in case of patients having all three factors, such as absence of abdominal symptoms, 
improvement of endoscopic findings and normalization or significant reduction of 
serum level of C-reactive protein. Clinical response was defined in case of those having 
two of all factors. 
2
CAI score: clinical activity index score 
3
20 patients with moderate UC: 20 patients with corticosteroid-dependent moderate UC 
were enrolled in Ricart’s trial. The range of clinical activity index score was 6 to 12. 
4
186 patients with moderate-severe UC: 186 patients with corticosteroid-dependent or 
-resistant moderate-severe UC were enrolled in Dignass’s trial. The mean clinical 
activity index score was 8.8. 
 





Figure 1: Literature screening and selection process. 
The search strategy identified a total of 400 citations. 383 of 400 citations were 
excluded and the remaining seventeen were retrieved and evaluated in more detail. Of 
17 studies, 9 were included in this meta-analysis. 
GMAA; granulocytes and monocytes adsorption apheresis 
 
Figure 2: The effect of granulocytes and monocytes adsorption apheresis compared with 
corticosteroids on rate of clinical remission and response in patients with active 
ulcerative colitis.  
(A) The effect of granulocytes and monocytes adsorption apheresis compared with 
corticosteroids on clinical remission rate in patients with active ulcerative colitis. 
(B) The effect of granulocytes and monocytes adsorption apheresis compared with 
corticosteroids on clinical response rate in patients with active ulcerative colitis. 
GMAA; granulocytes and monocytes adsorption apheresis 
M-H; Mantel-Haenszel 
CI; confidence interval 
 




Figure 3: The effect of granulocytes and monocytes adsorption apheresis compared with 
corticosteroids on clinical remission rate in patients with severe and moderate ulcerative 
colitis. 
(A) The effect of granulocytes and monocytes adsorption apheresis compared with 
corticosteroids on clinical remission rate in patients with severe ulcerative colitis. 
(B) The effect of granulocytes and monocytes adsorption apheresis compared with 
corticosteroids on clinical remission rate in patients with moderate ulcerative colitis. 
GMAA; granulocytes and monocytes adsorption apheresis 
M-H; Mantel-Haenszel 
CI; confidence interval 
 
 
Figure 4: The evaluation of therapeutic effect of granulocytes and monocytes adsorption 
apheresis on clinical remission rate in patients with active ulcerative colitis by 
comparing granulocytes and monocytes adsorption apheresis regimens. 
(A) The effect of 10 granulocytes and monocytes adsorption apheresis-sessions 
compared with 5 granulocytes and monocytes adsorption apheresis-sessions on clinical 
remission rate in patients with active ulcerative colitis. 




(B) The effect of intensive granulocytes and monocytes adsorption apheresis compared 
with weekly granulocytes and monocytes adsorption apheresis on clinical remission rate 
in patients with active ulcerative colitis. 
GMAA; granulocytes and monocytes adsorption apheresis 
M-H; Mantel-Haenszel 
CI; confidence interval 
 
Figure 5: The adverse events rate of granulocytes and monocytes adsorption apheresis 
compared with corticosteroids in patients with active ulcerative colitis. 
GMAA; granulocytes and monocytes adsorption apheresis 
M-H; Mantel-Haenszel 
CI; confidence interval 
 
Figure 1: Literature screening and selection process. 
 
The search strategy identified a total of 400 citations. 383 of 400 citations were excluded and the remaining seventeen were retrieved and evaluated 
in more detail. Of 17 studies, 9 were included in this meta-analysis. 
  
Figure 2: The effect of GMA compared with corticosteroids on rate of clinical remission and response in patients with active UC  
 
(A) The effect of GMAA compared with corticosteroids on clinical remission rate in patients with active UC. 
(B) The effect of GMAA compared with corticosteroids on clinical response rate in patients with active UC. 
GMAA; granulocytes and monocytes adsorption apheresis 
M-H; Mantel-Haenszel 
CI; confidence interval 
 
Figure 3: The effect of GMAA compared with corticosteroids on clinical remission rate in patients with severe and moderate UC. 
 
(A) The effect of GMAA compared with corticosteroids on clinical remission rate in patients with severe UC. 
(B) The effect of GMAA compared with corticosteroids on clinical remission rate in patients with moderate UC. 
GMAA; granulocytes and monocytes adsorption apheresis 
M-H; Mantel-Haenszel 
CI; confidence interval 
 
Figure 4: The evaluation of therapeutic effect of GMAA on clinical remission rate in patients with active UC by comparing GMAA regimens. 
 
(A) The effect of 10 GMAA-sessions compared with 5 GMAA-sessions on clinical remission rate in patients with active UC. 
(B) The effect of intensive GMAA compared with weekly GMAA on clinical remission rate in patients with active UC. 
GMAA; granulocytes and monocytes adsorption apheresis 
M-H; Mantel-Haenszel 
CI; confidence interval 
 
  
Figure 5: The adverse events rate of GMAA compared with corticosteroids in patients with active UC.  
 
GMAA; granulocytes and monocytes adsorption apheresis 
M-H; Mantel-Haenszel 
CI; confidence interval 
 
Table 1: Characteristics of included studies in this meta-analysis 
 
Original clinical activity score: Original scoring system based on clinical symptoms, endoscopic findings and inflammatory markers. Disappearance of two 
of three clinical factors (abdominal pain, bloody stool and diarrhea) and endoscopic findings of active UC (erosions, ulcers, mucous and bloody stool and 
indistinct vascular pattern), and normalization or significantly improvement of C-reactive protein were defined as clinical remission. Improvement of two of 
those three factors, such as clinical factors, endoscopic findings and level of C-reactive protein was defined as clinical response. 
CAI score: clinical activity index score 
